Amicus Therapeutics Inc (NASDAQ: FOLD) has seen a rise in its stock price by 3.76 in relation to its previous close of 11.43. However, the company has experienced a -1.17% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-01 that PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Is It Worth Investing in Amicus Therapeutics Inc (NASDAQ: FOLD) Right Now?
FOLD has 36-month beta value of 0.75. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FOLD is 286.50M, and currently, short sellers hold a 11.31% ratio of that float. The average trading volume of FOLD on March 28, 2024 was 3.14M shares.
FOLD’s Market Performance
The stock of Amicus Therapeutics Inc (FOLD) has seen a -1.17% decrease in the past week, with a -14.37% drop in the past month, and a -15.83% fall in the past quarter. The volatility ratio for the week is 3.68%, and the volatility levels for the past 30 days are at 4.26% for FOLD. The simple moving average for the past 20 days is -2.56% for FOLD’s stock, with a -4.16% simple moving average for the past 200 days.
Analysts’ Opinion of FOLD
Many brokerage firms have already submitted their reports for FOLD stocks, with Morgan Stanley repeating the rating for FOLD by listing it as a “Overweight.” The predicted price for FOLD in the upcoming period, according to Morgan Stanley is $20 based on the research report published on December 19, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $14. The rating they have provided for FOLD stocks is “Equal-Weight” according to the report published on September 09th, 2022.
Goldman gave a rating of “Neutral” to FOLD, setting the target price at $11 in the report published on April 13th of the previous year.
FOLD Trading at -6.46% from the 50-Day Moving Average
After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.60% of loss for the given period.
Volatility was left at 4.26%, however, over the last 30 days, the volatility rate increased by 3.68%, as shares sank -8.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.76% lower at present.
During the last 5 trading sessions, FOLD fell by -1.17%, which changed the moving average for the period of 200-days by -7.42% in comparison to the 20-day moving average, which settled at $12.12. In addition, Amicus Therapeutics Inc saw -16.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FOLD starting from MCGLYNN MARGARET G, who sale 7,500 shares at the price of $13.40 back on Mar 05 ’24. After this action, MCGLYNN MARGARET G now owns 59,289 shares of Amicus Therapeutics Inc, valued at $100,500 using the latest closing price.
MCGLYNN MARGARET G, the Director of Amicus Therapeutics Inc, sale 7,500 shares at $13.29 during a trade that took place back on Mar 04 ’24, which means that MCGLYNN MARGARET G is holding 59,289 shares at $99,675 based on the most recent closing price.
Stock Fundamentals for FOLD
Current profitability levels for the company are sitting at:
- -0.19 for the present operating margin
- 0.9 for the gross margin
The net margin for Amicus Therapeutics Inc stands at -0.38. The total capital return value is set at -0.13. Equity return is now at value -107.04, with -20.18 for asset returns.
Based on Amicus Therapeutics Inc (FOLD), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.17. The debt to equity ratio resting at 2.47. The interest coverage ratio of the stock is -3.18.
Currently, EBITDA for the company is -65.62 million with net debt to EBITDA at -2.09. When we switch over and look at the enterprise to sales, we see a ratio of 9.27. The receivables turnover for the company is 4.56for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
To put it simply, Amicus Therapeutics Inc (FOLD) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
